Symbols

Symbols

Prelude Stock Surges: Phio's PH-762 Shines in Trials!

Friday, Jun 6, 2025 4:00 pm ET1min read

Prelude Therapeutics Incorporated rose 5.32% intraday, with recent news from Phio Pharmaceuticals Corp.PHIO-- (NASDAQ: PHIO) potentially influencing the market sentiment. Phio PharmaceuticalsPHIO-- announced a strategic initiative to heighten awareness of potential applications of the broader INTASYL siRNA portfolio, which includes approximately 30 compounds. Additionally, positive interim safety and efficacy results were reported in the ongoing Phase 1b dose escalation clinical trial with the INTASYL compound PH-762 for the treatment of skin cancer.

Insightful stock picks for the savvy investor.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue